Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Comment by joe_trouton Jul 09, 2011 3:49am
364 Views
Post# 18813652

RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: Paper

RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: PaperNo, I am just more realistic about it is all. In my view GPD should already be up another 50 cents just on the fantastic results, but it's not. People have already been selling for weeks and now GPD is at the dumpy price of 0.99 cents where it should not be. You expect another haircut on top of what I already perceive as a haircut since all of the results, including 74M at 7.08 g/t have been sold off.

I will be in for an extra 100K plus shares if someone is so foolish as to sell me them for 0.75 cents or less. I am sure I won't be the only one loading the shares in. Maybe more sellers will come on line, but I doubt they will be so stupid about it as to indiscriminately sell at tremendous losses right in the face of excellent results. I just don't buy into that theory. I have seen crazier things, so I suppose it's not 100% out of the question. Just not very likely.

OH and I don't think prediction techniques using chart analysis amount to anything, especially in this sector. GPD determines where the chart goes with the drill bit along with shareholder sentiment. No way you can predict people's mood swings and what GPD will or will not pull out of the ground.
Bullboard Posts